Novel peptides and combination of peptides for use in immunotherapy against various tumors

Abstract

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

1 . A method of eliciting an immune response in a patient who has cancer, comprising administering to the patient an effective amount of an antibody specifically binding to an MHC class I or II molecule complexed with a HLA-restricted antigen consisting of the amino acid sequence selected from SEQ ID NO: 157, from SEQ ID NO: 1 to SEQ ID NO: 156, and from SEQ ID NO: 158 to SEQ ID NO: 288,
 wherein said cancer is selected from the group consisting of hepatocellular carcinoma (HCC), colorectal carcinoma (CRC), glioblastoma (GB), gastric cancer (GC), esophageal cancer (OSCAR), non-small cell lung cancer (NSCLC), pancreatic cancer (PC), renal cell carcinoma (RCC), benign prostate hyperplasia (BPH), prostate cancer (PCA), ovarian cancer (OC), melanoma, breast cancer (BRCA), chronic lymphocytic leukemia (CLL), Merkel cell carcinoma (MCC), small cell lung cancer (SCLC), Non-Hodgkin lymphoma (NHL), acute myeloid leukemia (AML), gallbladder cancer and cholangiocarcinoma (GBC CCC), urinary bladder cancer (UBC), and uterine cancer (UTC).   
     
     
         2 . The method of  claim 1 , wherein the antibody is a polyclonal antibody, a monoclonal antibody, or a chimeric antibody. 
     
     
         3 . The method of  claim 1 , wherein the antibody binds to the HLA-restricted antigen with a binding affinity of below 20 nanomolar. 
     
     
         4 . The method of  claim 1 , wherein the antibody binds to the MHC class I molecule complexed with the HLA-restricted antigen. 
     
     
         5 . The method of  claim 1 , wherein the antibody is humanized. 
     
     
         6 . The method of  claim 1 , wherein the effective amount of the antibody is from about 1 μg/kg to about 100 mg/kg of body weight per day. 
     
     
         7 . The method of  claim 1 , wherein the antibody is conjugated with a toxin. 
     
     
         8 . The method of  claim 1 , wherein the antibody is conjugated with an immune stimulating domain. 
     
     
         9 . The method of  claim 1 , wherein the cancer is HCC. 
     
     
         10 . The method of  claim 1 , wherein the cancer is UBC. 
     
     
         11 . The method of  claim 1 , wherein the cancer is AML. 
     
     
         12 . The method of  claim 1 , wherein the cancer is NHL. 
     
     
         13 . The method of  claim 1 , wherein the cancer is BRCA. 
     
     
         14 . The method of  claim 1 , wherein the cancer is CLL. 
     
     
         15 . The method of  claim 1 , wherein the cancer is GBC CCC. 
     
     
         16 . The method of  claim 1 , wherein the cancer is MEL. 
     
     
         17 . The method of  claim 1 , wherein the cancer is OC. 
     
     
         18 . The method of  claim 1 , wherein the cancer is OSCAR. 
     
     
         19 . The method of  claim 1 , wherein the cancer is SCLC. 
     
     
         20 . The method of  claim 1 , wherein the cancer is UTC.